Opens in a new tab

Can Stem Cell-Derived Particles Help Damaged Lungs Recover? A New Clinical Study Shows Promise

A Breath of Hope for Lung Health

Breathing is something most of us rarely think about until it becomes difficult. For individuals living with pulmonary fibrosis, even everyday activities can become challenging as scar tissue develops inside the lungs.

Pulmonary fibrosis causes lung tissue to become thicker and less flexible, making it harder for oxygen to move efficiently into the bloodstream. Symptoms often include shortness of breath, persistent coughing, and fatigue.

A 2025 study published in Signal Transduction and Targeted Therapy explored an innovative possibility: could microscopic particles released by umbilical cord-derived stem cells help improve lung function when delivered through inhalation?

How Can Stem Cells Help Without Being Transplanted?

The treatment involved extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells. These tiny particles act like biological delivery packages, carrying proteins, genetic material, and other molecules that help cells communicate with one another.

Researchers are particularly interested in their potential to influence inflammation and tissue repair; two processes closely connected to pulmonary fibrosis.

Unlike traditional stem cell therapies, this approach does not involve transplanting living cells. Instead, researchers used a nebulizer to turn a solution containing the vesicles into a fine mist that patients could inhale.

The goal was to deliver these potentially beneficial particles directly into the lungs.

Inside the Clinical Trial

Researchers conducted a Phase 1 randomized, single-blind, placebo-controlled clinical trial involving 24 patients with pulmonary fibrosis in China.

Participants were divided into two groups:

  • Treatment group: 12 patients received their usual medical care plus inhaled umbilical cord MSC-derived extracellular vesicles.
  • Control group: 12 patients continued their usual medical care and inhaled a saline solution instead.

Participants received nebulized treatments twice daily for seven consecutive days.

Researchers monitored lung function, respiratory symptoms, quality of life, and treatment safety. Clinical assessments continued through day 84, with additional follow-up extending to one year.

Encouraging Improvements in Breathing and Lung Function

The results revealed several promising differences between the groups. Patients receiving the extracellular vesicle treatment demonstrated significant improvements in two important lung function measurements:

  • Forced vital capacity (FVC): The amount of air a person can forcefully exhale after taking a deep breath.
  • Maximal voluntary ventilation (MVV): A measurement of how much air someone can move in and out of their lungs during rapid breathing.

Researchers also observed improvements in respiratory health questionnaires, including measures of coughing and limitations on daily activities.

These findings suggest that adding inhaled extracellular vesicles to conventional treatment may help improve certain aspects of breathing and respiratory well-being. However, not every lung function measurement showed a significant difference between groups.

What Did Lung Scans Reveal?

One particularly interesting finding came from the participants’ lung scans. Two patients with advanced post-inflammatory pulmonary fibrosis demonstrated visible improvements on CT imaging following treatment.

Researchers observed reductions in abnormal lung findings at day 28, with additional improvement by day 84.

Although most participants didn’t show comparable changes on their scans, these two cases raised an intriguing possibility that extracellular vesicles may influence processes associated with lung tissue damage.

Importantly, these observations don’t establish that the therapy reversed permanent lung scarring or regenerated healthy lung tissue.

What About Treatment Safety?

Safety was the primary focus of this early clinical trial. Encouragingly, all participants tolerated the inhaled treatment well, with no serious adverse events reported.

Researchers observed no meaningful treatment-related abnormalities in cardiac function, blood measurements, or liver and kidney function. No allergic reactions or treatment-related adverse events were reported during the follow-up period.

These findings provide encouraging initial safety evidence, although larger studies will be necessary to evaluate long-term risks.

A Promising Step Toward Cell-Free Regenerative Medicine

What makes this research particularly exciting is its use of cell-free regenerative medicine delivered through inhalation. Rather than introducing living stem cells into the body, researchers explored whether their naturally released particles could provide therapeutic benefits directly to affected lung tissue.

While the findings are encouraging, the trial involved only 24 patients and included several different forms of pulmonary fibrosis. Larger clinical trials are needed to confirm effectiveness, identify which patients might benefit most, and establish appropriate dosing.

Nevertheless, this study highlights an innovative direction in regenerative medicine, offering an early glimpse into how stem cell-derived extracellular vesicles might one day complement existing treatments for challenging lung conditions.

Source

Li M, Huang H, Wei X, et al. Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduction and Targeted Therapy. 2025;10:179. DOI: 10.1038/s41392-025-02262-3
Full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12134356/

Do you have questions?

We have answers. Speak with a Stemedix Care Coordinator today with no obligation. Give us a call!

Contact Us
Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.